Dublin-headquartered pharmaceutical firm Amryt Pharma has reported an increase in third quarter revenues and also upgraded its full year revenue guidance.
Amryt produces a range of medicines, including drugs for cholesterol disorders and leptin deficiencies, and is also developing a drug to treat a rare skin disorder called Epidermolysis Bullosa (EB).
In September, the company said that its topical therapeutic gel Filsuvez had demonstrated a significant increase in speed of wound healing in EB in a late-stage trial - the first treatment to do so.
Amryt said its revenues for the three months to the end of September rose by 19% to $49.3m from $41.4m the same time last year.
The company also reported a $3.6m operating loss before finance expenses in the third quarter, but raised its full year 2020 revenue guidance from $170-175m to $180-$182m.
Dr Joe Wiley, CEO of Amryt Pharma, said today's results demonstrate the positive performance and growth its commercial products are delivering alongside the significant progress it is achieving in its "exciting development pipeline" of new therapeutic drug candidates.
"The positive momentum we experienced during the first half of the year has continued through Q3 and I am very pleased with both our revenue growth and positive cash momentum," the CEO said.
Mr Wiley also said the company was very pleased with the positive results for Filsuvez from its EASE Phase 3 trial in EB.
"EASE is the first ever Phase 3 study to demonstrate positive data in this devastating disease and we look forward to submitting this data to regulatory authorities in both the US and Europe in early 2021," he said.
If approved, the company intends to launch the drug in the US in the fourth quarter of 2021 and in Europe in the first quarter of 2022.
